(A) Residues Thr60, Ser65, Thr66, Ser86 and Thr87 were mutated and KAP phosphorylation analyzed in 32P-labeled PCT3 cells overexpressing KAP mutants. Numbers in the lower panel of Fig. A and in the following panels were calculated by densitometric analyses of phosphorylated protein and normalized by total KAP protein levels. The ratio corresponding to KAP-WT protein was used as a reference in each case. * p<0,05 vs WT (Student-t test). (B) Individual domains that include T60A, ST65/66AA and ST86/87AA were also tested. As depicted in Fig. B, all three constructs resulted in a reduction in KAP phosphorylation. * p<0,05 vs WT (Student-t test). (C) New mutants that include T60A and ST65/66AA (KAP-DM) and residues T60A, ST65/66AA and ST86/87AA (KAP-TM) were also produced. The phosphorylation capacities of DM and TM constructs were assessed as explained in part A of this figure. * p<0,0001 vs WT (Student-t test).(D) Immunoprecipitation of KAP-WT and KAP-TM in transfected PCT3 cell extracts using anti-phospho-Thr antibodies (##), and further immunoblotting with anti-KAP specific antibodies showed that the Thr residues mutated in the KAP-TM form are phosphorylated in the WT form. Immunoprecipitation of KAP-WT cell extracts using anti-CycE antibodies was used as a negative control (#).* p<0,0001 vs WT (Student-t test).